Is TNYA or ENTX more profitable?

Tenaya Therapeutics' return on equity of -83.75% beat Entera Bio's return on equity. Company Net Margins Return on Equity Return on Assets Tenaya Therapeutics N/A -83.75% -66.53% Entera Bio N/A -147.19% -103.22%

Does the media favor TNYA or ENTX?

In the previous week, Entera Bio had 3 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 5 mentions for Entera Bio and 2 mentions for Tenaya Therapeutics. Tenaya Therapeutics' average media sentiment score of 0.54 beat Entera Bio's score of 0.04 indicating that Tenaya Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenaya Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Entera Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor TNYA or PBYI?

In the previous week, Puma Biotechnology had 1 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 3 mentions for Puma Biotechnology and 2 mentions for Tenaya Therapeutics. Puma Biotechnology's average media sentiment score of 1.00 beat Tenaya Therapeutics' score of 0.54 indicating that Puma Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenaya Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Puma Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer RGNX or TNYA?

In the previous week, REGENXBIO and REGENXBIO both had 2 articles in the media. REGENXBIO's average media sentiment score of 0.74 beat Tenaya Therapeutics' score of 0.54 indicating that REGENXBIO is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment REGENXBIO 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tenaya Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TNYA or ARVN?

In the previous week, Arvinas had 6 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 8 mentions for Arvinas and 2 mentions for Tenaya Therapeutics. Tenaya Therapeutics' average media sentiment score of 0.54 beat Arvinas' score of 0.43 indicating that Tenaya Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenaya Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Arvinas 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Tenaya Therapeutics (TNYA) Competitors

$0.41 -0.11 (-21.88%)

As of 02:32 PM Eastern

Compare

TNYA vs. ENTX, PBYI, RGNX, ARVN, and KMDA

Should you buy Tenaya Therapeutics stock or one of its competitors? Tenaya Therapeutics's main competitors and comparable companies include Entera Bio (ENTX), Puma Biotechnology (PBYI), REGENXBIO (RGNX), Arvinas (ARVN), and Kamada (KMDA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Tenaya Therapeutics compare to Entera Bio?

Tenaya Therapeutics (NASDAQ:TNYA) and Entera Bio (NASDAQ:ENTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

Tenaya Therapeutics has a beta of 2.87, indicating that its share price is 187% more volatile than the broader market. Comparatively, Entera Bio has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market.

In the previous week, Entera Bio had 3 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 5 mentions for Entera Bio and 2 mentions for Tenaya Therapeutics. Tenaya Therapeutics' average media sentiment score of 0.54 beat Entera Bio's score of 0.04 indicating that Tenaya Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tenaya Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Entera Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

90.5% of Tenaya Therapeutics shares are held by institutional investors. Comparatively, 14.1% of Entera Bio shares are held by institutional investors. 2.5% of Tenaya Therapeutics shares are held by insiders. Comparatively, 10.6% of Entera Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Tenaya Therapeutics' return on equity of -83.75% beat Entera Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenaya Therapeutics	N/A	-83.75%	-66.53%
Entera Bio	N/A	-147.19%	-103.22%

Tenaya Therapeutics presently has a consensus price target of $4.00, indicating a potential upside of 667.75%. Entera Bio has a consensus price target of $9.60, indicating a potential upside of 285.54%. Given Tenaya Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tenaya Therapeutics is more favorable than Entera Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Entera Bio has higher revenue and earnings than Tenaya Therapeutics. Entera Bio is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.53	N/A
Entera Bio	$40K	10,826.52	-$11.44M	-$0.35	N/A

Summary

Tenaya Therapeutics beats Entera Bio on 9 of the 14 factors compared between the two stocks.

How does Tenaya Therapeutics compare to Puma Biotechnology?

Tenaya Therapeutics (NASDAQ:TNYA) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

Puma Biotechnology has higher revenue and earnings than Tenaya Therapeutics. Tenaya Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.53	N/A
Puma Biotechnology	$228.40M	2.29	$31.11M	$0.52	19.46

In the previous week, Puma Biotechnology had 1 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 3 mentions for Puma Biotechnology and 2 mentions for Tenaya Therapeutics. Puma Biotechnology's average media sentiment score of 1.00 beat Tenaya Therapeutics' score of 0.54 indicating that Puma Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tenaya Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Puma Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tenaya Therapeutics has a beta of 2.87, suggesting that its share price is 187% more volatile than the broader market. Comparatively, Puma Biotechnology has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market.

Tenaya Therapeutics presently has a consensus price target of $4.00, suggesting a potential upside of 667.75%. Puma Biotechnology has a consensus price target of $6.00, suggesting a potential downside of 40.71%. Given Tenaya Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Tenaya Therapeutics is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

90.5% of Tenaya Therapeutics shares are owned by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are owned by institutional investors. 2.5% of Tenaya Therapeutics shares are owned by insiders. Comparatively, 22.2% of Puma Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Puma Biotechnology has a net margin of 11.50% compared to Tenaya Therapeutics' net margin of 0.00%. Puma Biotechnology's return on equity of 20.76% beat Tenaya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenaya Therapeutics	N/A	-83.75%	-66.53%
Puma Biotechnology	11.50%	20.76%	13.22%

Summary

Puma Biotechnology beats Tenaya Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Tenaya Therapeutics compare to REGENXBIO?

REGENXBIO (NASDAQ:RGNX) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

REGENXBIO has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market. Comparatively, Tenaya Therapeutics has a beta of 2.87, indicating that its stock price is 187% more volatile than the broader market.

In the previous week, REGENXBIO and REGENXBIO both had 2 articles in the media. REGENXBIO's average media sentiment score of 0.74 beat Tenaya Therapeutics' score of 0.54 indicating that REGENXBIO is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
REGENXBIO	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tenaya Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

88.1% of REGENXBIO shares are owned by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are owned by institutional investors. 14.2% of REGENXBIO shares are owned by company insiders. Comparatively, 2.5% of Tenaya Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

REGENXBIO currently has a consensus price target of $23.17, indicating a potential upside of 219.10%. Tenaya Therapeutics has a consensus price target of $4.00, indicating a potential upside of 667.75%. Given Tenaya Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Tenaya Therapeutics is more favorable than REGENXBIO.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
REGENXBIO	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Tenaya Therapeutics has a net margin of 0.00% compared to REGENXBIO's net margin of -112.58%. Tenaya Therapeutics' return on equity of -83.75% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
REGENXBIO	-112.58%	-220.07%	-46.04%
Tenaya Therapeutics	N/A	-83.75%	-66.53%

Tenaya Therapeutics has lower revenue, but higher earnings than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
REGENXBIO	$170.44M	2.81	-$193.88M	-$3.79	N/A
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.53	N/A

Summary

Tenaya Therapeutics beats REGENXBIO on 9 of the 14 factors compared between the two stocks.

How does Tenaya Therapeutics compare to Arvinas?

Tenaya Therapeutics (NASDAQ:TNYA) and Arvinas (NASDAQ:ARVN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

Tenaya Therapeutics presently has a consensus target price of $4.00, suggesting a potential upside of 667.75%. Arvinas has a consensus target price of $14.55, suggesting a potential upside of 112.65%. Given Tenaya Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Tenaya Therapeutics is more favorable than Arvinas.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Arvinas	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.50

Arvinas has a net margin of 2.94% compared to Tenaya Therapeutics' net margin of 0.00%. Arvinas' return on equity of 1.91% beat Tenaya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenaya Therapeutics	N/A	-83.75%	-66.53%
Arvinas	2.94%	1.91%	1.29%

Tenaya Therapeutics has a beta of 2.87, indicating that its share price is 187% more volatile than the broader market. Comparatively, Arvinas has a beta of 1.8, indicating that its share price is 80% more volatile than the broader market.

90.5% of Tenaya Therapeutics shares are held by institutional investors. Comparatively, 95.2% of Arvinas shares are held by institutional investors. 2.5% of Tenaya Therapeutics shares are held by company insiders. Comparatively, 7.3% of Arvinas shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Arvinas has higher revenue and earnings than Tenaya Therapeutics. Tenaya Therapeutics is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.53	N/A
Arvinas	$262.60M	1.68	-$80.80M	$0.10	68.40

In the previous week, Arvinas had 6 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 8 mentions for Arvinas and 2 mentions for Tenaya Therapeutics. Tenaya Therapeutics' average media sentiment score of 0.54 beat Arvinas' score of 0.43 indicating that Tenaya Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tenaya Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Arvinas	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Arvinas beats Tenaya Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Tenaya Therapeutics compare to Kamada?

Kamada (NASDAQ:KMDA) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

Kamada has a net margin of 11.60% compared to Tenaya Therapeutics' net margin of 0.00%. Kamada's return on equity of 8.37% beat Tenaya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kamada	11.60%	8.37%	5.85%
Tenaya Therapeutics	N/A	-83.75%	-66.53%

Kamada has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market. Comparatively, Tenaya Therapeutics has a beta of 2.87, meaning that its share price is 187% more volatile than the broader market.

Kamada currently has a consensus price target of $13.50, indicating a potential upside of 75.55%. Tenaya Therapeutics has a consensus price target of $4.00, indicating a potential upside of 667.75%. Given Tenaya Therapeutics' higher probable upside, analysts clearly believe Tenaya Therapeutics is more favorable than Kamada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kamada	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

In the previous week, Tenaya Therapeutics had 1 more articles in the media than Kamada. MarketBeat recorded 2 mentions for Tenaya Therapeutics and 1 mentions for Kamada. Tenaya Therapeutics' average media sentiment score of 0.54 beat Kamada's score of 0.40 indicating that Tenaya Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Kamada	Neutral
Tenaya Therapeutics	Positive

20.4% of Kamada shares are owned by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are owned by institutional investors. 36.1% of Kamada shares are owned by company insiders. Comparatively, 2.5% of Tenaya Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Kamada has higher revenue and earnings than Tenaya Therapeutics. Tenaya Therapeutics is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kamada	$180.46M	2.45	$20.20M	$0.38	20.24
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.53	N/A

Summary

Kamada beats Tenaya Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Tenaya Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TNYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TNYA vs. The Competition

Export

Metric	Tenaya Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$93.50M	$3.91B	$7.28B	$12.97B
Dividend Yield	N/A	3.65%	2.51%	22.89%
P/E Ratio	-0.79	12.99	275.40	25.37
Price / Sales	N/A	1,152.92	562.90	78.82
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	0.74	16.61	10.55	5.95
Net Income	-$90.60M	-$22.69M	$3.50B	$380.75M
7 Day Performance	-20.70%	-6.02%	-3.94%	-3.96%
1 Month Performance	-38.95%	-13.82%	-8.33%	-6.81%
1 Year Performance	-78.85%	6.88%	2.44%	-4.58%

Tenaya Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TNYA Tenaya Therapeutics	2.4783 of 5 stars	$0.41 -21.9%	$4.00 +882.8%	-73.7%	$93.50M	N/A	N/A	70	News Coverage Gap Down High Trading Volume
ENTX Entera Bio	2.9204 of 5 stars	$2.62 -8.4%	$9.60 +266.4%	-7.8%	$497.42M	$40K	N/A	21	News Coverage Short Interest Increase High Trading Volume
PBYI Puma Biotechnology	1.56 of 5 stars	$9.67 +1.7%	$6.00 -38.0%	+91.3%	$490.91M	$228.40M	18.60	179
RGNX REGENXBIO	2.9535 of 5 stars	$7.76 +4.4%	$23.17 +198.5%	-36.0%	$490.48M	$174.48M	N/A	371
ARVN Arvinas	3.2853 of 5 stars	$7.46 +0.7%	$14.55 +95.0%	-30.2%	$478.10M	$262.60M	74.61	246

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TNYA) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tenaya Therapeutics (TNYA) Competitors

TNYA vs. ENTX, PBYI, RGNX, ARVN, and KMDA

How does Tenaya Therapeutics compare to Entera Bio?

Summary

How does Tenaya Therapeutics compare to Puma Biotechnology?

Summary

How does Tenaya Therapeutics compare to REGENXBIO?

Summary

How does Tenaya Therapeutics compare to Arvinas?

Summary

How does Tenaya Therapeutics compare to Kamada?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNYA vs. The Competition

Tenaya Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tenaya Therapeutics (TNYA) Competitors

TNYA vs. ENTX, PBYI, RGNX, ARVN, and KMDA

How does Tenaya Therapeutics compare to Entera Bio?

Which has more volatility & risk, TNYA or ENTX?

Does the media favor TNYA or ENTX?

Do institutionals & insiders believe in TNYA or ENTX?

Is TNYA or ENTX more profitable?

Do analysts prefer TNYA or ENTX?

Which has stronger earnings & valuation, TNYA or ENTX?

Summary

How does Tenaya Therapeutics compare to Puma Biotechnology?

Which has stronger earnings & valuation, TNYA or PBYI?

Does the media favor TNYA or PBYI?

Which has more risk & volatility, TNYA or PBYI?

Do analysts prefer TNYA or PBYI?

Do institutionals and insiders have more ownership in TNYA or PBYI?

Is TNYA or PBYI more profitable?

Summary

How does Tenaya Therapeutics compare to REGENXBIO?

Which has more risk and volatility, RGNX or TNYA?

Does the media prefer RGNX or TNYA?

Do institutionals & insiders hold more shares of RGNX or TNYA?

Do analysts prefer RGNX or TNYA?

Is RGNX or TNYA more profitable?

Which has higher valuation & earnings, RGNX or TNYA?

Summary

How does Tenaya Therapeutics compare to Arvinas?

Do analysts prefer TNYA or ARVN?

Is TNYA or ARVN more profitable?

Which has more risk & volatility, TNYA or ARVN?

Do institutionals and insiders have more ownership in TNYA or ARVN?

Which has preferable valuation & earnings, TNYA or ARVN?

Does the media prefer TNYA or ARVN?

Summary

How does Tenaya Therapeutics compare to Kamada?

Is KMDA or TNYA more profitable?

Which has more volatility & risk, KMDA or TNYA?

Do analysts rate KMDA or TNYA?

Does the media prefer KMDA or TNYA?

Do insiders & institutionals believe in KMDA or TNYA?

Which has higher valuation & earnings, KMDA or TNYA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNYA vs. The Competition

Tenaya Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools